4CPS-188 Use of intranasal esketamine for treatment-resistant major depressive disorder

View at publisher Summarise with VIRAT
Authors: María Barba Llacer, Esperanza Gutiérrez Gutiérrez, V. Espinel Díez, A Velez Blanco, Susana Llamas Lorenzana, L Ortega Valín, X Casas Fernández, Juan Ayala Álvarez-Canal, M Flores Fernandez, A Fernández Vázquez, JJ Ortiz De Urbina González
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background and Importance Intranasal esketamine has been recently approved for the management of treatment-resistant major depressive disorder. Aim and Objectives This study aimed to evaluate whether intranasal esketamine use met funding criteria and its combination with selective serotonin reuptake inhibitors (SSRIs) or selective norepinephrine reuptake inhibitors (SNRIs) in adults aged 18–74 years unresponsive to at least three antidepressant strategies. Efficacy was assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS scale) at baseline and treatment end. Outcomes were classified as failure (6 months. Almost all (90%) received intranasal esketamine with an SSRI or SNRI, most frequently venlafaxine (51.8%). Regarding efficacy, 13 (43.3%) showed no response, 4 (13.3%) partial response, and 5 (16.6%) remission; data were unavailable for 8 (26.6%). Regarding safety, the following adverse effects were reported: dizziness in 25 patients (83.3%), headache in 6 patients (20%), dissociation in 2 patients (6.6%), nausea and drowsiness, both in 11 patients (36.6%), vertigo in 1 patient (3.3%), and increased blood pressure in 10 patients (33.3%). Conclusion and Relevance The use of intranasal esketamine in our hospital generally aligns with the established funding criteria. In terms of efficacy, although a significant proportion of patients did not achieve remission, a notable number showed partial responses. Regarding safety, while esketamine may represent a valid therapeutic option, its efficacy and safety profile should be carefully evaluated on a case-by-case basis. Conflict of Interest No conflict of interest

Fields of Study & Subjects

Treatment of Major Depression Electroconvulsive Therapy Studies Tryptophan and brain disorders

Publication details

Journal / source
European Journal of Hospital Pharmacy
Pages
A141.2–A141
Publication date
1 March 2026
Language
EN